Linaclotide

Base Information

• Chemical Name: Linaclotide
• CAS No.: 851199-59-2
• Molecular Formula: C₅₉H₇₉N₁₅O₂₁S₆
• Molecular Weight: 1526.76
• European Community (EC) Number: 812-291-9
• UNII: N0TXR0XR5X
• ChEMBL ID: CHEMBL3301675
• DSSTox Substance ID: DTXSID90234256
• Metabolomics Workbench ID: 151981
• NCI Thesaurus Code: C81001
• Nikkaji Number: J3.220.720K
• Pharos Ligand ID: GV17P376TZLV
• RXCUI: 1307404
• Wikidata: Q3832559
• Wikipedia: Linaclotide
• Mol file: 851199-59-2.mol

Synonyms:ASP-0456;ASP0456;linaclotide;Linaclotide Acetate;Linzess;MD-1100;MD-1100 acetate

Chemical Property of Linaclotide

Chemical Property:

• Boiling Point: 2045.0±65.0 °C(Predicted)
• PKA: 3.05±0.10(Predicted)
• PSA: 725.71000
• Density: 1.60
• LogP: -0.59300
• Storage Temp.: Hygroscopic, Refrigerator, under inert atmosphere
• Solubility.: DMSO (Slightly, Heated), Methanol ((Slightly, Heated)), Water (Slightly, Heated)
• XLogP3: -6.8
• Hydrogen Bond Donor Count: 19
• Hydrogen Bond Acceptor Count: 28
• Rotatable Bond Count: 13
• Exact Mass: 1525.3899216
• Heavy Atom Count: 101
• Complexity: 3030

Purity/Quality:

≥98% ^*data from raw suppliers

Linaclotide ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Drug Classes: Gastrointestinal Agents
• Canonical SMILES: CC1C(=O)NC2CSSCC3C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(NC(=O)CNC(=O)C(NC2=O)C(C)O)C(=O)NC(CC4=CC=C(C=C4)O)C(=O)O)C(=O)NC(CSSCC(C(=O)N3)N)C(=O)NC(C(=O)N5CCCC5C(=O)N1)CC(=O)N)CC6=CC=C(C=C6)O)CCC(=O)O
• Isomeric SMILES: C[C@H]1C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)CNC(=O)[C@@H](NC2=O)[C@@H](C)O)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)O)C(=O)N[C@@H](CSSC[C@@H](C(=O)N3)N)C(=O)N[C@H](C(=O)N5CCC[C@H]5C(=O)N1)CC(=O)N)CC6=CC=C(C=C6)O)CCC(=O)O
• Recent ClinicalTrials: A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation
• Recent EU Clinical Trials: A Phase 3, Open-label, Long-term Safety Study of Oral Linaclotide Administered to Pediatric Participants with Functional Constipation (FC) or Irritable Bowel Syndrome with Constipation (IBS-C)
• Recent NIPH Clinical Trials: Multicenter study to evaluate the efficacy of 1L Ascorbic acid PEG plus linaclotide for bowel preparation
• Description: In August 2012, the US FDA approved linaclotide (also referred to as MD-1100), a first-in-class, orally administered 14-amino acid peptide as a therapy for patients suffering from chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Linaclotide and its active metabolite MM-419447, which results from the cleavage of the C-terminal tyrosine residue by carboxypeptidase A, mimic the actions of the endogenous intestinal peptides guanylin (15 amino acids) and uroguanylin (16 amino acids) by activating guanylyl cyclase C (GC-C) on the intestinal epithelium. Activation of GC-C leads to increased intra- and extracellular levels of cGMP and activation of the CFTR ion channel, resulting in increased levels of HCO3-, Cl-, and water in the intestinal lumen and accelerated gastrointestinal transit. Based on an in vitro assaymeasuring the accumulation of cGMP in T84 cell exposed to an agonist, the EC50 of linaclotide at pH 7.0 was 99±17.5 nM. In preclinical studies in mice using the transit of activated charcoal as ameasure of efficacy, linaclotide at 100 μg/kg significantly accelerated transit compared to wild-type mice treated with charcoal only or GC-Cnullmice treatedwith and without linaclotide.118 Efficacy was also seen in rats treatedwith linaclotide atdoses of 5, 10, and 20 μg/kg. Linaclotide has been synthesized using conventional solid-phase peptide technology.
• Uses: Linaclotide is a guanylate cyclase-C agonist currently being studied in Phase 3 trials for the treatment of irritable bowel syndrome with constipation.

Technology Process of Linaclotide

There total 2 articles about Linaclotide which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 59.2%

C59H85N15O21S6 → D-linaclotide (851199-59-2)

Guidance literature:

With Oxidized glutathione; GLUTATHIONE; In aq. buffer; at 25 ℃; pH=8;

DOI:10.1016/j.cclet.2018.01.005

Reference yield: 51.7%

Cys1-Cys2-Glu3-Tyr4-Cys5-Cys6-Asn7-Pro8-Ala9-Cys10-Thr11-Gly12-Cys13-Tyr14 → L-linaclotide (851199-59-2)

Guidance literature:

With Oxidized glutathione; GLUTATHIONE; In aq. buffer; at 25 ℃; pH=8;

DOI:10.1016/j.cclet.2018.01.005

Refernces